Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Bristol-Myers Squibb Company PFD CONV 2

Current price
1 100 USD 0 USD (0.00%)
Last closed 1 100 USD
Sector Other
Industry Other
Exchange PINK
Capitalization 1 639 930 003 456 USD
Yield for 12 month -7.56 %
21.11.2021 - 28.11.2021

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in atrial fibrillation and the prevention and treatment of venous thromboembolic disorders; Orencia, a biological product that targets adult patients with active rheumatoid arthritis and prostate-specific antigen; and Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. The company's products also comprise Yervoy, a monoclonal antibody for the treatment of adults and pediatric patients with unresectable or metastatic melanoma; Empliciti, a human monoclonal antibody for the treatment of multiple myeloma; Baraclude, a potent and selective inhibitor of the hepatitis B virus; Sustiva, a non-nucleoside reverse transcriptase inhibitor for HIV and bulk efavirenz; Reyataz, a protease inhibitor for the treatment of HIV and combination therapy Evotaz; Daklinza, an oral small molecule NS5A replication complex inhibitor for the treatment of hepatitis C virus (HCV); and Sunvepra, an oral small molecule for the treatment of HCV. It sells products to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. Bristol-Myers Squibb Company has a research partnership with Sirenas; and a collaboration agreement with Nektar Therapeutics, Illumina, Inc., Janssen Pharmaceuticals, Inc., and Advantagene, Inc., as well as Tsinghua University. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Address:


WallStreet Target Price

P/E ratio


Dividend Yield

0.12 %

Current Year

+46 159 000 000 USD

Last Year

+46 385 000 000 USD

Current Quarter

+11 226 000 000 USD

Last Quarter

+11 337 000 000 USD

Current Year

+36 022 000 000 USD

Last Year

+36 445 000 000 USD

Current Quarter

+8 350 000 000 USD

Last Quarter

+8 771 000 000 USD

Key Figures BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Operating Margin TTM
PE Ratio 4444.4443
Return On Assets TTM
PEG Ratio
Return On Equity TTM
Wall Street Target Price
Revenue TTM
Book Value
Revenue Per Share TTM
Dividend Share 1.59 USD
Quarterly Revenue Growth YOY
Dividend Yield 0.12 %
Gross Profit TTM
Earnings Share
Diluted Eps TTM
Most Recent Quarter II 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BMYMP

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

71 %

Dividend History BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield 0.12 %
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date 01.09.2023

Stock Valuation BMYMP

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 4444.4443
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA
Price Book MRQ

Financials BMYMP

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators BMYMP

For 52 weeks

1 047.69 USD 1 448.19 USD
50 Day MA 1 125 USD
Shares Short Prior Month
200 Day MA 1 162.44 USD
Short Ratio
Shares Short
Short Percent